Hematologic Malignancy
Primary Cutaneous Non-Hodgkin Lymphoma
CI-CAN-00003738Explore in graph →
Hematologic67 active trials10 approved drugs
- NCIt
- C188114
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003738Explore in graph →
Rankings
6 current ranking rows (latest year per scope). Each row lists the scope, the formula version, the value and the exact inputs that produced it.
| Metric | Scope | Rank / eligible | Δ | Value | Percentile | Confidence | Formula | Generated | Inputs |
|---|---|---|---|---|---|---|---|---|---|
| Publications, last 5 years | World · both sexes · all ages · latest · all malignant entities | #2585 / 2,873 | = | 1 count | 10 | Medium confidence | ci-pubs-5y-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 5y (query stored per row)
inputs hash 531d42217f151c0dd79899a6 Trace lineage (admin) |
| Active clinical trials | World · both sexes · all ages · latest · all malignant entities | #240 / 1,654 | = | 67 count | 85.5 | Medium confidence | ci-active-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING)
inputs hash f2f5ed2084d93bba6dcb810e Trace lineage (admin) |
| Active Phase III trials | World · both sexes · all ages · latest · all malignant entities | #340 / 810 | = | 3 count | 58.1 | Medium confidence | ci-phase3-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … active statuses AND PHASE3 = ANY(phases)
inputs hash 56fba75197c8c0044b9e345f Trace lineage (admin) |
| Recruiting clinical trials | World · both sexes · all ages · latest · all malignant entities | #253 / 1,277 | = | 32 count | 80.3 | Medium confidence | ci-recruiting-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL
inputs hash 4352f89d0670b61272a585b3 Trace lineage (admin) |
| Sponsor concentration (HHI) | World · both sexes · all ages · latest · all malignant entities | #360 / 615 | = | 0.043 index (0–1) | 41.5 | High confidence | ci-sponsor-hhi-v1 | Sep 29, 2026 | showformula: Σ (active_trials_by_lead_sponsor / active_trials)² over the cancer and its descendants
|
| Trial termination share | World · both sexes · all ages · latest · all malignant entities | #125 / 454 | = | 0.38 ratio | 72.6 | High confidence | ci-trial-termination-v1 | Sep 29, 2026 | showformula: (terminated + withdrawn) / (completed + terminated + withdrawn) WHERE first_posted_date ≥ 2010-01-01 AND study_type = INTERVENTIONAL
|
Computed Ranks are competition ranks (ties share a rank). Percentile = share of eligible entities ranked at or below this one in the ranking direction.
"Deadliest" is ambiguous: annual deaths, age-standardized mortality rate, mortality-to-incidence ratio and 5-year survival rank cancers differently. CancerIndex publishes each as a separate metric.
inputs hash d0a365cf448b4492e5842c02
inputs hash b91f4c1d0fc49c7e7afbbdb1
Unmet need · computed
No research-gap components for this entity